Remove 2040 Remove Data Remove Epilepsy
article thumbnail

MyMD Pharmaceuticals President Chris Chapman, M.D. Named Medical Honoree of the Year by the Arthritis Foundation

Cannabis Law Report

Studies estimate that the number of people suffering from rheumatoid arthritis may rise to over 78 million by 2040. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. 1 Data published by Research and Markets, March 2018. MyMD: Robert Schatz. 646) 421-9523.